<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202956</url>
  </required_header>
  <id_info>
    <org_study_id>JL-HM-01-01</org_study_id>
    <nct_id>NCT00202956</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Bugusan (BGS)to Treat Osteoporosis.</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects on Biomarkers and Safety of Bugusan (BGS) in Postmenopausal Patients With Osteoporosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <brief_summary>
    <textblock>
      The objective is to evaluate the effects on biomarkers and safety of BGS in postmenopausal&#xD;
      patients with osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to evaluate the effects on biomarkers and safety of BGS in postmenopausal&#xD;
      patients with osteoporosis by a study of Randomized, Double Blind, Placebo-Controlled,&#xD;
      Parallel Group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2004</start_date>
  <completion_date>May 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bugusan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal women between the ages of 45 and 75 years with a natural menopause ≧ 6&#xD;
             months and serum E2 values &lt; 20 pg/ml, serum FSH values ≧ 25 mIU/mL;&#xD;
&#xD;
          2. Patients have bone mineral density &lt;-2.5 SD of T score at the lumbar spine (L2-L4);&#xD;
&#xD;
          3. All patients must sign the informed consent form (ICF) prior to the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any X-ray film that documents substantial scoliosis, or spinal secondary osteoporosis;&#xD;
&#xD;
          2. Any X-ray film that documents bone fracture within 3 month prior to the trial.&#xD;
&#xD;
          3. Medication such as estrogen, bisphosphonates, calcitonin, fluoride, glucocorticoids,&#xD;
             ipriflavone intake within 3 weeks prior to the trial;&#xD;
&#xD;
          4. Use of other Chinese medicine within 2 weeks prior to the trial;&#xD;
&#xD;
          5. Patients with significant renal function impairment (Creatinine&gt;2mg/dl) and liver&#xD;
             function impairment (AST and ALT &gt; 2 x the upper limit of normal range);&#xD;
&#xD;
          6. Patients have laboratory test abnormality, which in the investigator's opinion might&#xD;
             confound the study;&#xD;
&#xD;
          7. Patients have severe cardiac disease, e.g. unstable angina pectoris, myocardial&#xD;
             infarction, congestive heart failure (New York Heart Association Functional&#xD;
             Classification III and IV);&#xD;
&#xD;
          8. Patients have life threatening disease;&#xD;
&#xD;
          9. Patients are allergic to any of the composition of Chinese medicine;&#xD;
&#xD;
         10. Significant concomitant disease or medical history that could interfere with the study&#xD;
             as judged by the investigator;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Huey-Herng Sheu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huey-Herng Sheu</last_name>
    <phone>8860402359-2525</phone>
    <phone_ext>4004</phone_ext>
    <email>whhsheu@vghtc.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huey-Herng Sheu, Doctor</last_name>
      <phone>886-4-2359-2525</phone>
      <phone_ext>4004</phone_ext>
      <email>whhsheu@vghtc.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Huey-Herng Sheu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

